A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Community Fundraising Champions – Jennifer Barrett and Robert Akers
Since 2021, Jennifer Barrett, Robert Akers, and committee members Bev Seiver, Mia Clancy, Matthew Dumbrill, Alex Connell, have been hosting the Andrew...
Happy New Year from the MND NSW Carers Program
2025 was a big year for the MND Carers Program…. And 2026 is set to be even bigger! Let’s recap what we achieved together…. Our goal was to boost the...
Top 5 Frequently Asked Questions from December 2025
Welcome to this month’s insights from the MND NSW Info Line! We have rounded up the top 5 questions we’ve been asked lately from across NSW, ACT and N...
Every Moment Matters - Evaluating the Impact of MND
Being diagnosed with MND brings changes, challenges and extra considerations for a person living with the condition, as well as to their carers a...